ISRG.NASDAQIntuitive Surgical INC

10-K: Intuitive Surgical Reports Strong 2024 Growth, Driven by Procedure Volume and System Placements

Sentiment:

Annual Results

📋All filings for Intuitive Surgical INC
🔒Login to Follow

Intuitive Surgical's 2024 10-K filing reveals a robust year marked by significant revenue growth, increased procedure volumes, and strategic advancements in its product offerings.

Delay expectedThe report mentions that the company is in the midst of a phased launch of da Vinci 5 over several quarters, giving the company time to mature its supply and manufacturing processes for the new system.The report mentions that the company expects the introduction of the Ion system in South Korea to follow the refinement of our training pathways in the region and the gathering of local clinical and economic data.

Summary

  • Intuitive Surgical's 10-K filing for the year ended December 31, 2024, highlights a year of substantial growth and strategic progress.
  • Total revenue increased by 17% to $8.4 billion, driven by higher instruments and accessories revenue, systems revenue, and service revenue.
  • Approximately 2,683,000 da Vinci procedures were performed, representing a 17% increase from the previous year.
  • The company placed 1,526 da Vinci surgical systems, increasing the installed base to 9,902 systems worldwide.
  • The company also placed 271 Ion systems, increasing the installed base to 805 systems.
  • Gross profit margin improved to 67.5%, and operating income increased by 33% to $2.35 billion.
  • The company's cash, cash equivalents, and investments reached $8.83 billion.
  • The company is actively managing supply chain risks and monitoring the macroeconomic environment.
  • The company is expanding its product offerings with the da Vinci 5 and Ion systems and is seeking regulatory approvals in various markets.
  • The company is subject to ongoing legal proceedings and regulatory requirements, which could impact its business.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results and growth in key areas. However, it also acknowledges certain risks and challenges, preventing a higher score.

Positives

  • Strong revenue growth driven by increased procedure volumes and system placements.
  • Improved gross profit margin and operating income.
  • Significant cash reserves to fund future growth and investments.
  • Expansion of product offerings with the da Vinci 5 and Ion systems.
  • Growing installed base of da Vinci and Ion systems.
  • Continued adoption of robotic-assisted surgery in various specialties and geographic markets.

Negatives

  • The company is subject to ongoing legal proceedings and regulatory requirements, which could impact its business.
  • The company is facing increasing competition in the robotic-assisted surgical system industry, particularly in China.
  • The company is experiencing some supply chain constraints and inflationary pressures.
  • The company is monitoring the macroeconomic environment, which could impact its customers' ability to spend on capital equipment.
  • The company is subject to risks associated with real estate construction and development.

Risks

  • Competition from existing and emerging treatment options.
  • Failure to obtain or maintain regulatory approvals and certifications.
  • Product defects or performance problems leading to recalls.
  • Inability to protect intellectual property.
  • Macroeconomic conditions impacting customer spending.
  • Cybersecurity threats and information technology system failures.
  • Healthcare reform and changes in reimbursement policies.
  • Reliance on soleand single-sourced suppliers.
  • Failure to attract and retain key personnel.
  • Public health crises or epidemic diseases.
  • Ongoing and future global conflicts.

Future Outlook

The company expects to continue to invest in research and development and anticipates that research and development expenses will continue to increase in the future. The company expects capital investments to range between $650 million and $800 million in 2025, the majority of which will be facilities-related investments.

Industry Context

The report acknowledges the competitive landscape, with several companies developing new approaches and products for the MIS market. It also notes the increasing competition within China for robotic-assisted surgical systems.

Comparison to Industry Standards

  • The report does not provide a direct comparison to industry standards.
  • However, it mentions that the company's da Vinci surgical system is used primarily in general, gynecologic, urologic, cardiothoracic, and head and neck surgical procedures.
  • It also notes that the company's strategy is to provide hospitals with attractive clinical and economical solutions across the spectrum of procedure complexity.

Legal Proceedings

  • The company is currently named as a defendant in a number of individual product liability lawsuits filed in various state and federal courts.
  • On May 10, 2021, Surgical Instrument Service Company, Inc. (SIS) filed a complaint in the Northern District of California Court alleging antitrust claims against the Company relating to EndoWrist service, maintenance, and repair processes.
  • Three class action complaints were filed against the Company in the Northern District of California Court alleging antitrust allegations relating to the service and repair of certain instruments manufactured by the Company.
  • On September 18, 2024, Restore Robotics Repairs (Restore) filed a complaint in the United States District Court for the Northern District of Florida alleging antitrust claims against the Company relating to the service and replacement of X/Xi EndoWrist instruments for use with the da Vinci X and Xi surgical systems.

Stakeholder Impact

  • Shareholders: Positive impact due to strong financial performance and growth prospects.
  • Employees: Positive impact due to increased headcount and personnel-related expenses.
  • Customers: Positive impact due to expanded product offerings and improved clinical outcomes.
  • Suppliers: Positive impact due to increased purchase commitments and obligations.

Next Steps

  • Continue to expand procedure adoption and acceptance of our products.
  • Continue to invest in research and development.
  • Continue to seek regulatory approvals in various markets.
  • Continue to manage supply chain risks and monitor the macroeconomic environment.

Key Dates

DateDescription
1995Intuitive Surgical, Inc. was founded.
1999Intuitive launched its first da Vinci surgical system.
2000FDA cleared da Vinci for general laparoscopic surgery.
March 2000The Board adopted the ESPP.
March 2009The company had an active stock repurchase program.
April 2010Intuitive Surgical, Inc. stockholders approved the 2010 Incentive Award Plan.
March 2010The Patient Protection and Affordable Care Act was enacted.
October 2012Approval from the Japanese Ministry of Health, Labor, and Welfare (MHLW) for our da Vinci Si surgical system.
April 1, 2013An aggregate reduction in Medicare payments went into effect.
2013The company started entering into sales-type and fixed-payment operating lease arrangements directly with certain qualified customers.
2014The fourth-generation da Vinci Xi surgical system was launched.
March 2015Approval from the Japanese Ministry of Health, Labor, and Welfare (MHLW) for our da Vinci Xi surgical system.
April 2015The Board of Directors amended and restated the New Hire Plan.
2016The company entered into an agreement to form the Joint Venture.
2017The da Vinci X surgical system was commercialized.
April 2018Approval from the Japanese Ministry of Health, Labor, and Welfare (MHLW) for our da Vinci X surgical system.
2018The da Vinci SP surgical system was commercialized.
2019The FDA cleared our Ion endoluminal system.
2019The Joint Venture acquired certain assets related to the da Vinci distribution business of Chindex.
October 2019The New Hire Plan expired.
2020The company acquired Orpheus Medical Ltd.
July 1, 2020The United States-Mexico-Canada Agreement (USMCA) became effective.
November 2020The Directors Plan was terminated.
May 26, 2021The EU Medical Devices Regulation became effective.
June 17, 2021The U.S. Supreme Court dismissed the most recent judicial challenge to the ACA.
January 1, 2021The Medicines and Healthcare Products Regulatory Agency (MHRA) has been the sovereign regulatory authority responsible for the Great Britain medical device market.
May 1, 2021The EUUK Trade and Cooperation Agreement (the TCA) entered into force.
April 2022An additional eight da Vinci procedures were granted reimbursement in Japan.
July 2022The Board increased the authorized amount available under our Repurchase Program to $3.5 billion.
August 2022The company entered into an accelerated share repurchase program (the August ASR Program) with Goldman, Sachs & Co.
September 2022The August ASR Program was completed.
September 2022Regulatory clearance for the da Vinci SP surgical system in Japan.
October 2022The company entered into an accelerated share repurchase program (the October ASR Program) with Citibank, N.A.
December 2022The October ASR Program was completed.
January 2022The company received regulatory clearance in China to market our da Vinci Endoscope Plus.
February 2022The company received regulatory clearance in China to market both our 12 mm SureForm 45 stapler and SureForm 60 stapler and corresponding reloads.
January 2022The company received regulatory clearance in China to market our da Vinci Vessel Sealer Extend with up to 7 mm vascular indications.
February 2022Armed conflict escalated between Russia and Ukraine.
January 2025The U.S. presidential administration re-confirmed its intention to impose a 25% tariff on imports from Mexico and Canada into the United States as early as February 1, 2025.
June 2023The China National Health Commission published the 2023 Quota.
July 2023The Chinese government launched a campaign targeting the healthcare sector.
August 2023Our Intuitive-Fosun Pharma Joint Venture received a manufacturing license that permits the Joint Venture to manufacture our da Vinci Xi surgical system for sale to customers in China.
September 2023The company received regulatory clearance in South Korea for our Ion endoluminal system.
March 2023The company obtained European certification in accordance with the EU MDR for our Ion endoluminal system.
April 2023The company obtained FDA clearance for the use of our da Vinci SP surgical system in simple prostatectomy procedures.
October 2023Armed conflict escalated between Israel and Hamas.
October 2023An executive order was issued in October 2023 on the Safe, Secure and Trustworthy Development and Use of AI.
February 2024The FDA issued a final rule to amend and replace the QSR.
March 2024The company obtained FDA clearance for our da Vinci 5 surgical system.
April 2024An additional five da Vinci procedures were granted reimbursement in Japan.
April 2024The company obtained FDA clearance to extend the number of uses of our catheter instrument used with our Ion endoluminal system from five to eight uses.
March 2024The company received NMPA regulatory clearance for our Ion endoluminal system in China.
September 2024The company obtained FDA clearance for our redesigned 8 mm SureForm 30 stapler and 8 mm SureForm 30 Curved-Tip stapler instruments and reloads.
August 2024The company obtained regulatory clearance in Taiwan for our da Vinci SP surgical system.
January 2024The company obtained European certification in accordance with the EU MDR for our da Vinci SP surgical system.
October 2024The company obtained regulatory clearance in South Korea for our da Vinci 5 surgical system.
December 2024The company obtained European certification in accordance with the EU MDR for our E-200 generator.
July 2023The company received regulatory clearance for our E-200 generator in Japan and South Korea.
November 2022The company obtained FDA clearance for our E-200 generator.
December 2024The company obtained FDA clearance for the use of our da Vinci SP surgical system in colorectal surgical procedures.
July 2024The company obtained FDA clearance for the use of our da Vinci SP surgical system in general thoracoscopic surgical procedures.
January 31, 2025The date of the report.
January 21, 2025Intuitive announced that it has entered into a definitive agreement with the current Intuitive technology distributors ab medica, Abex, Excelencia Robotica, and their affiliates to acquire the da Vinci and Ion distribution businesses in Italy, Spain, Portugal, Malta, and San Marino, and associated territories.

Keywords

Intuitive Surgical, da Vinci, Ion, robotic surgery, minimally invasive surgery, procedure volume, system placements, financial results, 10-K, regulatory, instruments, accessories, service, revenue, gross profit, operating income

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.